Literature DB >> 15996583

The evaluation of the local tolerance of vaginal formulations containing dapivirine using the Slug Mucosal Irritation test and the rabbit vaginal irritation test.

Marijke M M Dhondt1, Els Adriaens, Jens Van Roey, Jean Paul Remon.   

Abstract

The purpose of this study was to evaluate the local tolerance of vaginal gels (three gels containing dapivirine, the placebo gel, and Conceptrol) with the Slug Mucosal Irritation test and to compare the results with those of the rabbit vaginal irritation test. The irritation potential on the slug mucosa was assessed by the mucus production caused by a repeated treatment for 5 successive days. Additionally, membrane damage was estimated by the protein and enzyme release. By means of a classification prediction model the formulations were classified into four irritation classes. The effect of a 10-day intravaginal application of the gels on the rabbit vaginal and cervical mucosa was evaluated by means of macroscopic and microscopic examination. The placebo and dapivirine gels induced no irritation of the slug mucosa (low mucus production and protein release, no enzyme release) and no vaginal or cervical irritation in rabbits. Conceptrol caused severe irritation of the slug mucosa (increased mucus production, protein release, and enzyme release) and irritation of the rabbit vagina and cervix. The results obtained with the Slug Mucosal Irritation test were comparable to those of the rabbit vaginal irritation test.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15996583     DOI: 10.1016/j.ejpb.2005.01.012

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  7 in total

1.  Using the Slug Mucosal Irritation Assay to Investigate the Tolerability of Tablet Excipients on Human Skin in the Context of the Use of a Nipple Shield Delivery System.

Authors:  Richard Kendall; Joke Lenoir; Stephen Gerrard; Rebekah L Scheuerle; Nigel K H Slater; Catherine Tuleu
Journal:  Pharm Res       Date:  2017-02-13       Impact factor: 4.200

2.  Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.

Authors:  Claire J Forbes; Deborah Lowry; Leslie Geer; Ronald S Veazey; Robin J Shattock; Per Johan Klasse; Mark Mitchnick; Laurie Goldman; Lara A Doyle; Brendan C O Muldoon; A David Woolfson; John P Moore; R Karl Malcolm
Journal:  J Control Release       Date:  2011-08-12       Impact factor: 9.776

Review 3.  Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.

Authors:  Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-01-12

4.  Potential Mucosal Irritation Discrimination of Surface Disinfectants Employed against SARS-CoV-2 by Limacus flavus Slug Mucosal Irritation Assay.

Authors:  Marco Alfio Cutuli; Antonio Guarnieri; Laura Pietrangelo; Irene Magnifico; Noemi Venditti; Laura Recchia; Katia Mangano; Ferdinando Nicoletti; Roberto Di Marco; Giulio Petronio Petronio
Journal:  Biomedicines       Date:  2021-04-14

5.  Safety study of an antimicrobial peptide lactocin 160, produced by the vaginal Lactobacillus rhamnosus.

Authors:  Sara E Dover; Alla A Aroutcheva; S Faro; Michael L Chikindas
Journal:  Infect Dis Obstet Gynecol       Date:  2007

6.  Rationale and Safety Assessment of a Novel Intravaginal Drug-Delivery System with Sustained DL-Lactic Acid Release, Intended for Long-Term Protection of the Vaginal Microbiome.

Authors:  Hans Verstraelen; Chris Vervaet; Jean-Paul Remon
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

Review 7.  Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.

Authors:  Fernando Notario-Pérez; Roberto Ruiz-Caro; María-Dolores Veiga-Ochoa
Journal:  Drug Des Devel Ther       Date:  2017-06-15       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.